He is a board-certified Radiation Oncologist and specializes in treatment of lung cancer. Dr. Diehn’s research programs span basic, translational and clinical studies. He has made significant contributions in a number of areas, including in cancer stem cell biology and cancer genomics, and his work has been recognized with numerous honors, including the NIH Director’s New Innovator Award. Dr. Diehn’s group recently developed a next-generation sequencing-based method for detection of circulating tumor DNA called CAPP-Seq. Further development and clinical application of this approach are major ongoing research efforts.